The Houston-based endoluminal surgical robotic technology developer earmarked the funding to aid its development efforts. It expects the funds to fuel the advancement of its flexible endoluminal robot for minimally invasive procedures.
EndoQuest designed its platform to address unmet needs in gastrointestinal and other endoluminal surgeries. It developed a system that offers precision and flexibility to improve patient outcomes. The proprietary technology navigates and performs procedures within the body’s lumina spaces, allowing for minimally invasive interventions.
The platform makes it possible for therapeutic endoscopists and surgeons to operate through a trans-oral or trans-anal approach. EndoQuest featured on MassDevice’s list of 16 surgical robotics companies you need to know in 2022.
Legacy investors CE Ventures Limited and McNair Interests led the financing round along with new investor Puma Venture Capital. EndoQuest believes the investment reflects a vote of confidence in its cutting-edge robotic technology.
The company expects the newly acquired capital to help drive key initiatives, such as R&D, regulatory milestones and commercialization. It believes the funds strengthen the company’s position as “the frontrunner in flexible endoluminal robotics.”
“Our investors share our vision of leveraging robotics to redefine the possibilities in minimally invasive procedures,” said Kurt Azarbarzin, CEO of EndoQuest Robotics. “This financing enables us to continue innovating and refining our technology, ultimately improving patient care and transforming the future of endoluminal interventions.”
